Month: April 2024

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminib ELVN-001 was well tolerated with no ≥ Grade 3 treatment-related non-hematologic toxicities reported Company to host virtual event with Key Opinion Leaders at 8:00 AM ET Today BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001...

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Written by Customer Service on April 11, 2024. Posted in Public Companies.

– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties – – Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 – – Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer – NEW HAVEN, Conn., April 11, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS)...

Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call

Written by Customer Service on April 11, 2024. Posted in Public Companies.

DURHAM, N.C., April 11, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link. A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations...

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Written by Customer Service on April 11, 2024. Posted in Public Companies.

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” that will be presented during the “Multiple Sclerosis: Therapeutics and Clinical Decision Making” session at the Annual Meeting of the American Academy of Neurology, to be held April 13-18, 2024 in Denver, Colorado. Presentation Information:Presenter: Tarun Singhal, M.B.B.S., M.D. (Associate Professor of Neurology, Harvard Medical School, and Associate Neurologist, Brigham and Women’s Hospital, a founding member of Mass General Brigham...

ConnectOne Bancorp, Inc. to Host 2024 First Quarter Results Conference Call on April 25, 2024

Written by Customer Service on April 11, 2024. Posted in Public Companies.

ENGLEWOOD CLIFFS, N.J., April 11, 2024 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today announced that it plans to release results for the first quarter ended March 31, 2024, before the market opens on Thursday, April 25, 2024. Management will also host a conference call and audio webcast at 10:00 a.m. ET on April 25, 2024, to review the Company’s financial performance and operating results. Chairman and Chief Executive Officer Frank Sorrentino III and Senior Executive Vice President and Chief Financial Officer William S. Burns will host the call. The conference call dial-in number is 1 (646) 307-1963, access code 6725677. Please dial in at least five minutes before the start of the call to register. An audio webcast of the conference...

Microbix Presenting at the 2024 Bloom Burton Conference

Written by Customer Service on April 11, 2024. Posted in Public Companies.

MISSISSAUGA, Ontario, April 11, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Center, North Building, on April 16 and 17, 2024. The Conference provides an opportunity to connect with Canadian, U.S., and international investors who are interested in the latest developments in the Canadian healthcare and life sciences sector. Microbix’s CEO and President, Cameron Groome, will make an in-person group presentation to investors on Tuesday, April 16 at 10:30 AM Eastern Time. Senior management will also participate in multiple one-on-one meetings with investors at the Conference....

Company Provides Operational Update for Monterey County Oil Producing Assets

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Combined Oil Production Stabilized at 75 Barrels Per Day Bakersfield, CA, April 11, 2024 (GLOBE NEWSWIRE) — Trio Petroleum Corp (NYSE American: “TPET”, “Trio” or the “Company”), a California-based oil and gas company, today provided an update on its oil producing assets in Monterey County, California, including at the Presidents Field (“Presidents”) of the South Salinas Project and at the McCool Ranch Field (“McCool Ranch”). “We are pleased to provide this operational update on our two oil producing assets in Monterey County,” commented Michael Peterson, CEO of Trio Petroleum. “The Company currently operates two highly promising, proven petroleum assets in Monterey County in the Presidents Field and the McCool Ranch, and we are very encouraged by our recent operational results at both fields.” “Bringing these wells back online...

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Written by Customer Service on April 11, 2024. Posted in Mergers And Acquisitions.

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Companies to host webcast today, April 11, 2024 at 8:30 a.m. EDT SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive...

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Written by Customer Service on April 11, 2024. Posted in Mergers And Acquisitions.

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade’s αβ iT platform spanning across cancer and autoimmune diseases PHILADELPHIA, April 11, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent...

The Lovesac Company Reports Fourth Quarter and Fiscal 2024 Financial Results

Written by Customer Service on April 11, 2024. Posted in Earnings Releases And Operating Results.

Fourth Quarter Net Sales Growth of 5.0%Fiscal Year Net Sales Growth of 7.5% STAMFORD, Conn., April 11, 2024 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World’s Most Adaptable Couch, today announced financial results for the fourth quarter and fiscal 2024, which ended February 4, 2024. Note: Lovesac’s fourth quarter and fiscal 2024 results contain an additional, non-comparable week, or the “53rd week”, when compared to the fourth quarter and full year results for the respective 52- and 13-week periods ended January 29, 2023 (“fiscal 2023”), and full year guidance for the 52-week fiscal year ending February 2, 2025 (“fiscal 2025”). Unless stated otherwise, financial metrics discussed in this release, such as net...

Month: April 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals